CL2015001397A1 - Compuestos derivados de 4-amino-7,8-dihidropirimido[5,4-f][1,4]oxazepin-5(6h)-ona, inhibidores de diacilglicerol aciltransferasa; composicion farmaceutica y el uso en el tratamiento de la obesidad. - Google Patents
Compuestos derivados de 4-amino-7,8-dihidropirimido[5,4-f][1,4]oxazepin-5(6h)-ona, inhibidores de diacilglicerol aciltransferasa; composicion farmaceutica y el uso en el tratamiento de la obesidad.Info
- Publication number
- CL2015001397A1 CL2015001397A1 CL2015001397A CL2015001397A CL2015001397A1 CL 2015001397 A1 CL2015001397 A1 CL 2015001397A1 CL 2015001397 A CL2015001397 A CL 2015001397A CL 2015001397 A CL2015001397 A CL 2015001397A CL 2015001397 A1 CL2015001397 A1 CL 2015001397A1
- Authority
- CL
- Chile
- Prior art keywords
- dihydropyrimido
- oxazepin
- obesity
- amino
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3593DE2012 | 2012-11-23 | ||
IN750DE2013 | 2013-03-14 | ||
IN3172DE2013 | 2013-10-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015001397A1 true CL2015001397A1 (es) | 2015-08-28 |
Family
ID=50776577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015001397A CL2015001397A1 (es) | 2012-11-23 | 2015-05-22 | Compuestos derivados de 4-amino-7,8-dihidropirimido[5,4-f][1,4]oxazepin-5(6h)-ona, inhibidores de diacilglicerol aciltransferasa; composicion farmaceutica y el uso en el tratamiento de la obesidad. |
Country Status (31)
Country | Link |
---|---|
US (1) | US20150322082A1 (es) |
EP (2) | EP3492474B1 (es) |
JP (1) | JP6279600B2 (es) |
KR (1) | KR102176463B1 (es) |
CN (1) | CN104918620B (es) |
AU (1) | AU2013347843B2 (es) |
BR (1) | BR112015011982A8 (es) |
CA (1) | CA2892304C (es) |
CL (1) | CL2015001397A1 (es) |
CY (1) | CY1121426T1 (es) |
DK (1) | DK2922551T3 (es) |
EA (1) | EA031114B1 (es) |
ES (1) | ES2708626T3 (es) |
HK (1) | HK1214757A1 (es) |
HR (1) | HRP20190099T1 (es) |
HU (1) | HUE042483T2 (es) |
IL (1) | IL238835B (es) |
LT (1) | LT2922551T (es) |
ME (1) | ME03315B (es) |
MX (1) | MX363484B (es) |
NZ (1) | NZ630436A (es) |
PE (1) | PE20150967A1 (es) |
PH (1) | PH12015501109B1 (es) |
PL (1) | PL2922551T3 (es) |
PT (1) | PT2922551T (es) |
RS (1) | RS58539B1 (es) |
SG (1) | SG11201503761WA (es) |
SI (1) | SI2922551T1 (es) |
UA (1) | UA115079C2 (es) |
WO (1) | WO2014081994A1 (es) |
ZA (1) | ZA201503304B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018052818A (ja) * | 2015-01-28 | 2018-04-05 | 武田薬品工業株式会社 | スルホンアミド化合物 |
WO2018093698A1 (en) | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | Indole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100795462B1 (ko) * | 2006-09-27 | 2008-01-16 | 한국생명공학연구원 | 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
US20090036425A1 (en) * | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
US20090076275A1 (en) * | 2007-09-19 | 2009-03-19 | David Robert Bolin | Diacylglycerol acyltransferase inhibitors |
AR066169A1 (es) * | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
US8324385B2 (en) * | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
WO2011121350A1 (en) | 2010-04-01 | 2011-10-06 | Astrazeneca Ab | 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors |
RS55006B1 (sr) * | 2011-05-20 | 2016-11-30 | Glaxosmithkline Intellectual Property (No 2) Ltd | Nova jedinjenja kao inhibitori diacilglicerol aciltransferaze |
-
2013
- 2013-11-22 UA UAA201506216A patent/UA115079C2/uk unknown
- 2013-11-22 RS RS20190081A patent/RS58539B1/sr unknown
- 2013-11-22 EA EA201590982A patent/EA031114B1/ru unknown
- 2013-11-22 PL PL13856479T patent/PL2922551T3/pl unknown
- 2013-11-22 CA CA2892304A patent/CA2892304C/en not_active Expired - Fee Related
- 2013-11-22 SG SG11201503761WA patent/SG11201503761WA/en unknown
- 2013-11-22 HU HUE13856479A patent/HUE042483T2/hu unknown
- 2013-11-22 NZ NZ630436A patent/NZ630436A/en not_active IP Right Cessation
- 2013-11-22 EP EP18203369.6A patent/EP3492474B1/en active Active
- 2013-11-22 ES ES13856479T patent/ES2708626T3/es active Active
- 2013-11-22 LT LTEP13856479.4T patent/LT2922551T/lt unknown
- 2013-11-22 US US14/646,403 patent/US20150322082A1/en not_active Abandoned
- 2013-11-22 MX MX2015006533A patent/MX363484B/es unknown
- 2013-11-22 BR BR112015011982A patent/BR112015011982A8/pt active Search and Examination
- 2013-11-22 ME MEP-2019-14A patent/ME03315B/me unknown
- 2013-11-22 AU AU2013347843A patent/AU2013347843B2/en not_active Ceased
- 2013-11-22 EP EP13856479.4A patent/EP2922551B1/en active Active
- 2013-11-22 JP JP2015544141A patent/JP6279600B2/ja not_active Expired - Fee Related
- 2013-11-22 PT PT13856479T patent/PT2922551T/pt unknown
- 2013-11-22 CN CN201380069807.4A patent/CN104918620B/zh not_active Expired - Fee Related
- 2013-11-22 KR KR1020157016270A patent/KR102176463B1/ko active IP Right Grant
- 2013-11-22 WO PCT/US2013/071376 patent/WO2014081994A1/en active Application Filing
- 2013-11-22 DK DK13856479.4T patent/DK2922551T3/en active
- 2013-11-22 SI SI201331321T patent/SI2922551T1/sl unknown
- 2013-11-22 PE PE2015000657A patent/PE20150967A1/es unknown
-
2015
- 2015-05-12 ZA ZA2015/03304A patent/ZA201503304B/en unknown
- 2015-05-14 IL IL238835A patent/IL238835B/en active IP Right Grant
- 2015-05-19 PH PH12015501109A patent/PH12015501109B1/en unknown
- 2015-05-22 CL CL2015001397A patent/CL2015001397A1/es unknown
-
2016
- 2016-03-09 HK HK16102704.5A patent/HK1214757A1/zh not_active IP Right Cessation
-
2019
- 2019-01-16 HR HRP20190099TT patent/HRP20190099T1/hr unknown
- 2019-01-29 CY CY20191100120T patent/CY1121426T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015000331A1 (es) | Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal. | |
CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
CL2007002974A1 (es) | Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1. | |
CL2013001654A1 (es) | Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
CL2015001250A1 (es) | Compuestos derivados de triazolopirazinas, inhibidores de brd4; preparacion farmaceutica; y su uso en el tratamiento y/o la prevencion de cancer, tal como cancer de pulmon, higado, colon, cerebro, tiroides, mamas, entre otros. | |
CL2016002169A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados. | |
CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
CL2013002125A1 (es) | Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia. | |
BRPI1013698A2 (pt) | métodos para tratamento com o uso de terapia de combinação | |
BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
RS55927B1 (sr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova primena kao lek | |
CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
IT1403847B1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
AR125920A2 (es) | Composiciones que comprenden vortioxetina y donepezil | |
DK3040336T3 (da) | Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande | |
CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
CL2014003325A1 (es) | Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer | |
BRPI0912687A2 (pt) | uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia | |
CL2014001959A1 (es) | Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer. | |
CL2014003525A1 (es) | Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension. | |
CL2014001862A1 (es) | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. | |
CL2015001458A1 (es) | Composición simbiotica y el uso de la misma. | |
BR112013023575A2 (pt) | derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes |